Assessment of Minimal Residual Disease By Next-Generation Sequencing and Fluorodeoxyglucose-Positron Emission Tomography in Patients with Relapsed/Refractory Multiple Myeloma Treated with Venetoclax in Combination with Carfilzomib and Dexamethasone | Zendy

Luciano J. Costa | Zendy; Nicholas Burwick | Zendy; Andrzej Jakubowiak | Zendy; Jonathan L. Kaufman | Zendy; Fernando Cabanillas | Zendy; Monique Dail | Zendy; Sudeep Karve | Zendy; Abdullah Al Masud | Zendy; Xiaoqing Yang | Zendy; Orlando F. Bueno | Zendy; Sarah R. Mudd | Zendy; Jeremy A. Ross | Zendy; Faith E. Davies | Zendy

Open Access

Assessment of Minimal Residual Disease By Next-Generation Sequencing and Fluorodeoxyglucose-Positron Emission Tomography in Patients with Relapsed/Refractory Multiple Myeloma Treated with Venetoclax in Combination with Carfilzomib and Dexamethasone

Author(s) -

Luciano J. Costa,

Nicholas Burwick,

Andrzej Jakubowiak,

Jonathan L. Kaufman,

Fernando Cabanillas,

Monique Dail,

Sudeep Karve,

Abdullah Al Masud,

Xiaoqing Yang,

Orlando F. Bueno,

Sarah R. Mudd,

Jeremy A. Ross,

Faith E. Davies

Publication year - 2020

Publication title -

blood

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.515

H-Index - 465

eISSN - 1528-0020

pISSN - 0006-4971

DOI - 10.1182/blood-2020-134737

Subject(s) - medicine , minimal residual disease , venetoclax , carfilzomib , positron emission tomography , multiple myeloma , cohort , regimen , dexamethasone , nuclear medicine , fluorodeoxyglucose , bone marrow , gastroenterology , oncology , lenalidomide , leukemia , chronic lymphocytic leukemia

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research